Lilly’s Retevmo wins US nod for specific lung, thyroid cancers
The selective RET kinase inhibitor was cleared under the regulator’s accelerated approval process
Read More
Tag: selpercatinib
Lilly launches first of its kind trial for RET fusion-positive NSCLC
Selpercatinib was designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
